The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Personalized treatment strategies based on smoking history in lung cancer
Abhishek Shankar, MD, All India Institute of Medical Sciences, Delhi, India, comments on the importance of collecting smoking status data in clinical trials, which can help understand the response to immunotherapy among smokers. This information can provide insights into the relationship between smoking status and treatment outcomes. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think in coming days, we’ll see, I think recently we got published in Lancet Oncology. In this publication, we talked about every clinical trial should have a smoking, you know, status data, which will consist of, you know, frequency, intensity, you know, tobacco quit, including tobacco cessation efforts, smoking cessation efforts. So that will answer many questions probably and there is a need to understand this you know response to immunotherapy better response to immunotherapy among smokers in a better way because now it’s you know mutational you know burden related to the smoker that that helps to get the better outcome
This transcript is AI-generated...
So I think in coming days, we’ll see, I think recently we got published in Lancet Oncology. In this publication, we talked about every clinical trial should have a smoking, you know, status data, which will consist of, you know, frequency, intensity, you know, tobacco quit, including tobacco cessation efforts, smoking cessation efforts. So that will answer many questions probably and there is a need to understand this you know response to immunotherapy better response to immunotherapy among smokers in a better way because now it’s you know mutational you know burden related to the smoker that that helps to get the better outcome
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
